Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer
- PMID: 18410797
- DOI: 10.1053/j.seminoncol.2008.02.008
Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer
Abstract
Despite the recent trend toward treatment of early stage breast cancer aggressively with anthracyclines and taxanes, nearly half of those women will have metastatic recurrence. Moreover, because of the increasing prior exposure to these drugs, far more women facing first-line therapy for recurrent disease will now have developed anthracycline- and taxane-refractory metastatic breast cancer (ATRMBC), presenting a major therapeutic challenge. A number of established drugs are showing promise in this setting: capecitabine alone or combined with lapatinib; gemcitabine; vinorelbine; and oxaliplatin. At the same time, a variety of new drugs are emerging for potential use in ATRMBC. Among the drugs in clinical development that have shown promising activity include novel classes of compounds (camptothecins and epothilones), newer members of established classes (pemetrexed and vinflunine), and agents with novel mechanisms of action (the mitosis inhibitor E7389 and the ascidian-derived anticancer compound trabectedin). Several molecularly targeted agents are also being evaluated in ATRMBC, including interleukin-2 receptor-binding denileukin diftitox, and 17-(allylamino)-17-demethoxygeldanamycin (17-AAG), which inhibits the protein chaperone heat shock protein 90.
Similar articles
-
[New anti-cancer agents--from cytotoxic systemic chemotherapy to target-based agents].Gan To Kagaku Ryoho. 2005 Jun;32(6):783-8. Gan To Kagaku Ryoho. 2005. PMID: 15984516 Review. Japanese.
-
Rationale for the use of gemcitabine in breast cancer (Review).Int J Oncol. 2004 Feb;24(2):389-98. doi: 10.3892/ijo.24.2.389. Int J Oncol. 2004. PMID: 14719116 Review.
-
Monotherapy options in the management of metastatic breast cancer.Semin Oncol. 2003 Apr;30(2 Suppl 3):6-10. doi: 10.1053/sonc.2003.37268. Semin Oncol. 2003. PMID: 12722018 Review.
-
[Treatment possibilities in breast cancer progressing after anthracyclines and/or taxanes].Magy Onkol. 2010 Mar;54(1):9-16. doi: 10.1556/MOnkol.54.2010.1.2. Magy Onkol. 2010. PMID: 20350863 Review. Hungarian.
-
Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.Eur J Cancer. 2017 May;76:205-215. doi: 10.1016/j.ejca.2017.02.011. Epub 2017 Mar 27. Eur J Cancer. 2017. PMID: 28360015 Clinical Trial.
Cited by
-
Baseline interleukin-6 is a prognostic factor for patients with metastatic breast cancer treated with eribulin.Breast Cancer Res Treat. 2023 Dec;202(3):575-583. doi: 10.1007/s10549-023-07086-9. Epub 2023 Sep 21. Breast Cancer Res Treat. 2023. PMID: 37733188 Free PMC article.
-
Codelivery of chemotherapeutics via crosslinked multilamellar liposomal vesicles to overcome multidrug resistance in tumor.PLoS One. 2014 Oct 17;9(10):e110611. doi: 10.1371/journal.pone.0110611. eCollection 2014. PLoS One. 2014. PMID: 25330237 Free PMC article.
-
Advances in the management of metastatic breast cancer: options beyond first-line chemotherapy.Curr Oncol. 2012 Apr;19(2):91-105. doi: 10.3747/co.19.1024. Curr Oncol. 2012. PMID: 22514495 Free PMC article.
-
Multi-drug delivery to tumor cells via micellar nanocarriers.Int J Pharm. 2011 Oct 31;419(1-2):281-6. doi: 10.1016/j.ijpharm.2011.07.033. Epub 2011 Jul 27. Int J Pharm. 2011. PMID: 21820041 Free PMC article.
-
Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance.Oncogene. 2016 Feb 25;35(8):990-1002. doi: 10.1038/onc.2015.152. Epub 2015 May 11. Oncogene. 2016. PMID: 25961928 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
